ALK-Abelló B A/S
ALK-Abelló B A/S
0,40 %
1 498,00 DKK
6,00
Kurs
1 498,00
Hög
1 500,00
Förändring
0,40 %
Låg
1 472,00
Uppdaterad
17:10:00
Öppen
1 492,00
Factsheet for ALK-Abelló B A/S
Company Profile
Description
Alk-Abello is a biotechnology company that focuses on the pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.
Key Stats
Website: http://www.alk-abello.com
Headquarter country: Denmark
Employees: 1 827
Market Cap (at close 22-07-2019): DKK 16B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 198,00 204,90 24,90 38,90 32,30
Forward Price/Earnings 69,00
Price/Free Cash Flow 61,10 31,30 138,10 66,70
Return on Assets -3,50 -3,20 6,00 9,00 5,40
Return on Equity -5,30 -5,10 9,70 13,60 7,90
Return on Invested Capital -4,00 -4,10 7,70 11,70 7,10
Dividend


Dividend/Share:5,00
Ex. Dividend Date:2017-12-31
Trailing Dividend Yield:0,66
Payout Ratio:0,00
Date Currency Amount
2017-03-31 DKK 5,00
2016-03-31 DKK 5,00
2015-03-31 DKK 5,00
2014-03-31 DKK 5,00
2013-03-31 DKK 5,00
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 2 915,00 2 910,00 3 005,00 2 569,00 2 433,00
Gross Profit 1,63 1,64 2,01 1,73 1,70
Gross Margin % 56,02% 56,43% 66,92% 67,46% 69,75%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 154,00 227,00 664,00 573,00 451,00
Net income -170,00 -158,00 270,00 344,00 181,00
Basic Earnings Per Share -15,64 -15,93 27,51 35,45 18,74
Operating Income -0,10 -0,08 0,54 0,29 0,31
Operating Margin % -3,29% -2,75% 18,04% 11,41% 12,86%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -95,00 -387,00 405,00 183,00 320,00
Capital Expenditures -178,00 -267,00 -225,00 -199,00 -202,00
Free Cash Flow -273,00 -654,00 180,00 -16,00 118,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 1 999,00 2 155,00 1 951,00 1 536,00 1 032,00 1 029,00
Long Term Assets 2 866,00 2 803,00 2 848,00 2 716,00 2 387,00 2 239,00
Total Assets 4 865,00 4 958,00 4 799,00 4 252,00 3 419,00 3 268,00
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 726,00 666,00 807,00 919,00 524,00 502,00
Long Term Liabilities 1 002,00 1 117,00 636,00
Total Liabilities 1 668,00 1 924,00 1 555,00
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings 3 110,00 3 266,00 2 752,00 2 582,00 2 237,00 2 175,00
Treasury Stock
Total Stockholder Equity 3 179,00 3 290,00 2 875,00 2 697,00 2 354,00 2 249,00
Net Tangible Assets 2 454,00 2 538,00 2 111,00 1 938,00 1 691,00 1 575,00